We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

47 hedge funds and large institutions have $6.66M invested in Cue Biopharma in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.14% more ownership

Funds ownership: 0.78% → 0.92% (+0.14%)

8% less funds holding

Funds holding: 51 → 47 (-4)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

49% less capital invested

Capital invested by funds: $13M → $6.66M (-$6.32M)

Holders
47
Holders Change
-4
Holders Change %
-7.84%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
10
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
+$1.35M
2
GWMR
GC Wealth Management RIA
Massachusetts
+$735K
3
TCBWMS
Texas Capital Bank Wealth Management Services
Texas
+$250K
4
AWM
Angeles Wealth Management
California
+$116K
5
BFM
Boothbay Fund Management
New York
+$57.2K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$93.3K
2
Bank of America
Bank of America
North Carolina
-$71.6K
3
Squarepoint
Squarepoint
New York
-$61.7K
4
TSS
Two Sigma Securities
New York
-$28.4K
5
NL
Navalign LLC
California
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$6K +$12.8K +695 New
PIWA
27
Prevail Innovative Wealth Advisors
Kansas
$5.8K – – –
Morgan Stanley
28
Morgan Stanley
New York
$5.68K -$5.46K -297 -32%
Goldman Sachs
29
Goldman Sachs
New York
$4.39K -$18 -1 -0.2%
SWM
30
SeaCrest Wealth Management
New York
$3.87K – – –
HighTower Advisors
31
HighTower Advisors
Illinois
$3.34K +$6.69K +364 New
Barclays
32
Barclays
United Kingdom
$1.84K – – –
GG
33
Gleason Group
Kentucky
$1.83K – – –
NMG
34
New Millennium Group
Utah
$1.76K +$3.53K +192 New
NFSG
35
Newbridge Financial Services Group
Florida
$916 – – –
Wells Fargo
36
Wells Fargo
California
$783 -$10.4K -568 -87%
Simplex Trading
37
Simplex Trading
Illinois
$780 -$1.4K -76 -47%
GSWM
38
Golden State Wealth Management
California
$611 – – –
T
39
Tidemark
California
$458 – – –
PWA
40
Physician Wealth Advisors
Utah
$308 – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$209 – – –
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$127 -$165 -9 -39%
Jones Financial Companies
43
Jones Financial Companies
Missouri
$122 +$239 +13 New
MCM
44
MAI Capital Management
Ohio
$107 – – –
TM
45
Torren Management
California
$99 +$202 +11 New
AAG
46
Armstrong Advisory Group
Massachusetts
$37 – – –
IA
47
IFP Advisors
Florida
$31 – – –
JP Morgan Chase
48
JP Morgan Chase
New York
$1 -$551 -30 Closed
Squarepoint
49
Squarepoint
New York
– -$61.7K -2,860 Closed
TSS
50
Two Sigma Securities
New York
– -$28.4K -1,317 Closed
1
2
3

CUE Hedge Fund Activity: Q4 2025 in Review

47 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2025, worth a combined $6.66M — down 49% from $13M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CUE and 7 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was Lion Point Capital, opening a new position worth an estimated $1.35M. The largest seller was UBS Group, cutting an estimated $93.3K.

  • 47 institutional investors held Cue Biopharma (CUE) as of Q4 2025, down from 51 in Q3 2025.
  • Funds reported $6.66M of Cue Biopharma stock for Q4 2025, down 49% quarter-over-quarter.
  • 7 funds opened new Cue Biopharma positions in Q4 2025 and 11 closed out, a net change of -4 holders.
  • The largest Cue Biopharma buyer in Q4 2025 was Lion Point Capital, an estimated $1.35M added.
  • The largest Cue Biopharma seller in Q4 2025 was UBS Group, an estimated $93.3K sold.

Based on aggregated 13F filings for Q4 2025.